Development and Validation of a Novel All-Inclusive LC-MS-MS Designer Drug Method
| Autor: | Erin C Strickland, Allyson L Mellinger, Gregory L. McIntire, Oneka T Cummings |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Drug
medicine.drug_class Health Toxicology and Mutagenesis media_common.quotation_subject Metabolite Context (language use) Toxicology Machine learning computer.software_genre 01 natural sciences Analytical Chemistry Designer Drugs 03 medical and health sciences chemistry.chemical_compound Forensic Toxicology 0302 clinical medicine Limit of Detection Tandem Mass Spectrometry Synthetic cannabinoids medicine Environmental Chemistry Humans 030216 legal & forensic medicine Butylone media_common Chemical Health and Safety business.industry Cannabinoids 010401 analytical chemistry Reproducibility of Results 0104 chemical sciences Designer drug chemistry Mitragynine Pentylone Artificial intelligence business computer medicine.drug Chromatography Liquid |
| Zdroj: | Journal of analytical toxicology. 43(3) |
| ISSN: | 1945-2403 |
| Popis: | Designer drugs including synthetic cannabinoids and synthetic cathinones are an increasing problem due to the ease of access to these compounds. They present analytical challenges inasmuch as the compound structures are numerous and growing within each class. Typically each class of designer compounds is analyzed separately due to differences in chemistry, desired cut-offs or other reasons. Physicians treating "high-risk" patients typically order tests for all "illicit" substances which can span several test classes. Despite that multiple classes of designer drugs are ordered together, there has not been a comprehensive confirmatory test developed to date. Presented here is a novel comprehensive designer drug LC-MS-MS method that combines synthetic cannabinoids and synthetic cathinones, etizolam, a designer benzodiazepine and mitragynine (kratom), a natural product analgesic. This method improves laboratory throughput with a cycle time of ~4.5 min which affords resolution of crucial isomers, such as ethylone and butylone. Development of this method also provided an opportunity to update the list of compounds within the method. Analytes with fewer than five positive specimens in a year of testing with previous separate methods were removed as old and not current. New analytes were added based on reports from NMS Laboratories and the US Drug Enforcement Administration testing and drug seizures, which included etizolam, its major metabolite α-hydroxyetizolam as well as newer synthetic cannabinoids (5-fluoro ADB metabolite 7, AB-FUBINACA metabolite 3, AB-FUBINACA metabolite 4 and MDMB-FUBINACA metabolite M1) and synthetic cathinones (N-ethyl pentylone). Finally, the impact of the new analytes and cut-off changes are discussed in context with patient results from the first 4 months of testing after implementation of the method in the lab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|